ECM
ARGS

Exchange Capital Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Exchange Capital Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-50
Closed -$5K – 242
2016
Q4 		$5K Hold
50
– – ﹤0.01% 176
2016
Q3 		$5K Hold
50
– – ﹤0.01% 202
2016
Q2 		$6K Buy
+50
New +$6.67K ﹤0.01% 201

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Exchange Capital Management's ARGS Position: Q1 2017 in Review

Exchange Capital Management sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 50 shares — an estimated $5K sold.

Exchange Capital Management first reported a position in ARGS in Q2 2016 and held it in 3 quarters. The position peaked at $6K in Q2 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

  • Exchange Capital Management reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Exchange Capital Management sold 50 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $5K.
  • Exchange Capital Management first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 3 quarters.
  • Exchange Capital Management's Argos Therapeutics, Inc. position peaked at $6K in Q2 2016.
  • 43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on Exchange Capital Management's 13F filing for Q1 2017, filed 11 May 2017.